WHEREAS, Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics; and

WHEREAS, While ongoing treatment with these medications can be necessary, prolonged use can also lead to Tardive Dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, fingers, or toes that can impact people physically, socially, and emotionally; and

WHEREAS, It is estimated that TD affects approximately 600,000 people in the United States and approximately 65 percent of people with TD remain undiagnosed, making it important to raise awareness about the symptoms; and

WHEREAS, It is important for people taking these medications be monitored for TD by a health care provider. Regular screening for TD in these patients is recommended by the American Psychiatric Association; and

WHEREAS, Clinical research has led to the approval of treatments for adults with TD by the United States Food and Drug Administration. Recognition and treatment of TD can make a positive impact on the lives of many people experiencing psychotic and mood disorders; and

WHEREAS, Anyone experiencing uncontrollable, abnormal, and repetitive movements should be empowered to consult their health care provider regarding their symptoms to determine appropriate treatment; now, therefore, be it

Resolved by the Senate of the State of California, That the Senate proclaims the week of May 6, 2024, as Tardive Dyskinesia Awareness Week in California, and commends the observance of the week to all residents of the state; and be it further

Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.

WHEREAS, Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics; and

WHEREAS, While ongoing treatment with these medications can be necessary, prolonged use can also lead to Tardive Dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, fingers, or toes that can impact people physically, socially, and emotionally; and

WHEREAS, It is estimated that TD affects approximately 600,000 people in the United States and approximately 65 percent of people with TD remain undiagnosed, making it important to raise awareness about the symptoms; and

WHEREAS, It is important for people taking these medications be monitored for TD by a health care provider. Regular screening for TD in these patients is recommended by the American Psychiatric Association; and

WHEREAS, Clinical research has led to the approval of treatments for adults with TD by the United States Food and Drug Administration. Recognition and treatment of TD can make a positive impact on the lives of many people experiencing psychotic and mood disorders; and

WHEREAS, Anyone experiencing uncontrollable, abnormal, and repetitive movements should be empowered to consult their health care provider regarding their symptoms to determine appropriate treatment; now, therefore, be it

Resolved by the Senate of the State of California, That the Senate proclaims the week of May 6, 2024, as Tardive Dyskinesia Awareness Week in California, and commends the observance of the week to all residents of the state; and be it further

Resolved, That the Secretary of the Senate transmit copies of this resolution to the author for appropriate distribution.

 THIRD READING 

Bill No: SR 87

Author: Blakespear (D)

Introduced: 4/10/24

Vote: Majority

SUBJECT: Tardive Dyskinesia Awareness Week

SOURCE: Neurocrine Biosciences

DIGEST:

This resolution proclaims the week of May 6, 2024, as Tardive Dyskinesia Awareness Week in California, and commends the observance of the week to all residents of the state.

ANALYSIS: This resolution makes the following legislative findings:

1. Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics.
2. While ongoing treatment with these medications can be necessary, prolonged use can also lead to Tardive Dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, fingers, or toes that can impact people physically, socially, and emotionally.
3. It is estimated that TD affects approximately 600,000 people in the United States and approximately 65 percent of people with TD remain undiagnosed, making it important to raise awareness about the symptoms.
4. It is important for people taking these medications be monitored for TD by a health care provider. Regular screening for TD in these patients is recommended by the American Psychiatric Association.

This resolution proclaims the week of May 6, 2024, as Tardive Dyskinesia Awareness Week in California, and commends the observance of the week to all residents of the state.

Related/Prior Legislation

The following are the most recent measures relating to Tardive Dyskinesia Awareness Week:

• SR 30 (Blakespear, 2023) – adopted by the Senate on May 8, 2023.
• SR 67 (Archuleta, 2022) – adopted by the Senate on May 9, 2022.
• SR 20 (Archuleta, 2021) – adopted by the Senate on May 3, 2021.
• SR 73 (Archuleta, 2020) – adopted by the Senate on June 11, 2020.

FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No

SUPPORT: (Verified 4/15/24)

Neurocrine Biosciences (source)

OPPOSITION: (Verified 4/15/24)

None received

Prepared by: Russell Manning / SFA / (916) 651-1520

4/17/24 15:49:55

**** END ****